Samsca approved in Japan for rare kidney disorder
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical's aquaretic agent Samsca (tolvaptan) has received its first approval worldwide, in Japan, for the indication of autosomal dominant polycystic kidney disease (ADPKD).